NAS:ILMN (USA) Also trade in: Austria Germany Mexico UK

Illumina Inc

$ 344 2.72 (0.8%)
Volume: 737,875 Avg Vol (1m): 942,482
Market Cap $: 50.57 Bil Enterprise Value $: 48.78 Bil
P/E (TTM): 60.14 P/B: 12.86
Earnings Power Value 44.97
Net Current Asset Value 7.65
Tangible Book 19.99
Projected FCF 76.11
Median P/S Value 228.63
Graham Number 50.73
Peter Lynch Value 115.09
DCF (FCF Based) 58.88
DCF (Earnings Based) 162.84
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 2.07
Cash-To-Debt ranked higher than
62.07% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
ILMN: 2.07
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.69, Med: 1.74, Max: 16544
Current: 2.07
0.69
16544
Equity-to-Asset 0.54
Equity-to-Asset ranked lower than
51.46% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
ILMN: 0.54
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.36, Med: 0.54, Max: 0.94
Current: 0.54
0.36
0.94
Debt-to-Equity 0.44
Debt-to-Equity ranked higher than
51.22% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
ILMN: 0.44
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.47, Max: 1.5
Current: 0.44
0
1.5
Debt-to-EBITDA 1.51
Debt-to-EBITDA ranked higher than
70.69% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
ILMN: 1.51
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.96, Med: 1.74, Max: 3.41
Current: 1.51
0.96
3.41
Interest Coverage 14.25
Interest Coverage ranked lower than
53.99% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
ILMN: 14.25
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 5.3, Med: 9.45, Max: 17.52
Current: 14.25
5.3
17.52
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 11.19
DISTRESS
GREY
SAFE
Beneish M-Score -2.50
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 35.54%
WACC 9.51%

Profitability & Growth : 9/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 25.59
Operating Margin ranked higher than
88.84% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
ILMN: 25.59
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 17.88, Med: 23.11, Max: 28.47
Current: 25.59
17.88
28.47
Net Margin % 25.06
Net Margin ranked higher than
94.61% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
ILMN: 25.06
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 8.21, Med: 16.41, Max: 26.38
Current: 25.06
8.21
26.38
ROE % 24.30
ROE ranked higher than
94.63% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
ILMN: 24.3
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 7.62, Med: 17.54, Max: 29.32
Current: 24.3
7.62
29.32
ROA % 13.09
ROA ranked higher than
91.60% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
ILMN: 13.09
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 4.29, Med: 9.38, Max: 15.22
Current: 13.09
4.29
15.22
ROC (Joel Greenblatt) % 76.19
ROC (Joel Greenblatt) ranked higher than
97.68% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
ILMN: 76.19
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 56.69, Med: 82.61, Max: 135.02
Current: 76.19
56.69
135.02
3-Year Total Revenue Growth Rate 14.50
3-Year Revenue Growth Rate ranked higher than
80.22% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
ILMN: 14.5
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -1, Med: 21, Max: 156.2
Current: 14.5
-1
156.2
3-Year Total EBITDA Growth Rate 14.50
3-Year EBITDA Growth Rate ranked higher than
78.65% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
ILMN: 14.5
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 27.3, Max: 119.6
Current: 14.5
0
119.6
3-Year EPS w/o NRI Growth Rate 21.50
3-Year EPS w/o NRI Growth Rate ranked higher than
74.23% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
ILMN: 21.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 26.5, Max: 56.4
Current: 21.5
0
56.4

» ILMN's 30-Y Financials

Financials (Next Earnings Date: 2019-07-30)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ILMN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621511    SIC : 8071
Compare XAMS:PHIA NYSE:IQV XSWX:LONN NAS:IDXX NYSE:A NYSE:MTD NYSE:LH TSE:6869 NYSE:WAT SHSE:603259 NYSE:DGX NAS:EXAS XTER:SRT NAS:DXCM XPAR:BIM NYSE:PKI NYSE:BIO NYSE:QGEN XPAR:ERF NAS:ICLR
Traded in other countries ILU.Germany 0J8Z.UK
Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina Inc is a major player in life science tools for analyzing genetic material. Revenue from microarray and genome sequencing machines and disposables make up most of the company's revenue, but approximately 10% of the company's sales come from sequencing services. Essentially all of Illumina's growth stems from the company's genome sequencing products, which include the company's high-throughput NovaSeq and HiSeq instruments in addition to its benchtop NextSeq, MiSeq, and MiniSeq, and iSeq product lines.

Ratios

Current vs industry vs history
PE Ratio (TTM) 60.14
PE Ratio ranked lower than
90.27% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
ILMN: 60.14
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 32.02, Med: 69.22, Max: 302.86
Current: 60.14
32.02
302.86
Forward PE Ratio 52.91
Forward P/E ranked lower than
95.00% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
ILMN: 52.91
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 60.14
PE without NRI ranked lower than
87.61% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
ILMN: 60.14
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 32.02, Med: 69.22, Max: 302.86
Current: 60.14
32.02
302.86
Price-to-Owner-Earnings 73.21
Price-to-Owner-Earnings ranked lower than
63.16% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
ILMN: 73.21
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 20.62, Med: 56.82, Max: 97.42
Current: 73.21
20.62
97.42
PB Ratio 12.86
PB Ratio ranked lower than
74.29% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
ILMN: 12.86
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.88, Med: 9.07, Max: 23.59
Current: 12.86
2.88
23.59
PS Ratio 15.14
PS Ratio ranked lower than
75.65% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
ILMN: 15.14
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 3.54, Med: 10.07, Max: 17.19
Current: 15.14
3.54
17.19
Price-to-Free-Cash-Flow 62.52
Price-to-Free-Cash-Flow ranked lower than
77.50% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
ILMN: 62.52
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 13.31, Med: 45.84, Max: 102.59
Current: 62.52
13.31
102.59
Price-to-Operating-Cash-Flow 47.41
Price-to-Operating-Cash-Flow ranked lower than
79.38% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
ILMN: 47.41
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 10.31, Med: 32.76, Max: 344.72
Current: 47.41
10.31
344.72
EV-to-EBIT 50.45
EV-to-EBIT ranked lower than
74.58% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
ILMN: 50.45
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 17, Med: 40.5, Max: 247.7
Current: 50.45
17
247.7
EV-to-EBITDA 42.27
EV-to-EBITDA ranked lower than
78.79% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
ILMN: 42.27
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 12.6, Med: 32.6, Max: 135.6
Current: 42.27
12.6
135.6
EV-to-Revenue 14.36
EV-to-Revenue ranked lower than
72.73% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
ILMN: 14.36
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 2.8, Med: 9.9, Max: 17.4
Current: 14.36
2.8
17.4
PEG Ratio 2.18
PEG Ratio ranked higher than
60.42% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
ILMN: 2.18
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.67, Med: 1.91, Max: 13.47
Current: 2.18
0.67
13.47
Shiller PE Ratio 132.59
Shiller PE Ratio ranked lower than
100.00% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
ILMN: 132.59
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 99.64, Med: 195.79, Max: 3600
Current: 132.59
99.64
3600
Current Ratio 3.66
Current Ratio ranked higher than
78.00% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
ILMN: 3.66
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.99, Med: 3.91, Max: 60.21
Current: 3.66
0.99
60.21
Quick Ratio 3.33
Quick Ratio ranked higher than
81.60% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
ILMN: 3.33
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.87, Med: 3.61, Max: 60.21
Current: 3.33
0.87
60.21
Days Inventory 130.98
Days Inventory ranked higher than
52.45% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
ILMN: 130.98
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 111.78, Med: 133.48, Max: 147.41
Current: 130.98
111.78
147.41
Days Sales Outstanding 49.12
Days Sales Outstanding ranked higher than
69.61% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
ILMN: 49.12
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 54.51, Med: 61.29, Max: 86.41
Current: 49.12
54.51
86.41
Days Payable 47.62
Days Payable ranked higher than
67.38% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
ILMN: 47.62
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 52.47, Med: 64.5, Max: 93.62
Current: 47.62
52.47
93.62

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -0.10
3-Year Share Buyback Rate ranked higher than
76.11% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
ILMN: -0.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -13.6, Med: -4.6, Max: -0.1
Current: -0.1
-13.6
-0.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 17.21
Price-to-Tangible-Book ranked lower than
74.88% of 207 companies
in the Diagnostics & Research industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
ILMN: 17.21
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.17, Med: 8.67, Max: 461.34
Current: 17.21
1.17
461.34
Price-to-Projected-FCF 4.52
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
81.33% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
ILMN: 4.52
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.53, Med: 4.44, Max: 42.17
Current: 4.52
1.53
42.17
Price-to-DCF (Earnings Based) 2.11
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked lower than
100.00% of 17 companies
in the Diagnostics & Research industry.
Industry Max: 6.59, Med: 1.86, Min: 0.72
ILMN: 2.11
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 1.89, Med: 3.67, Max: 7.44
Current: 2.11
1.89
7.44
Price-to-Median-PS-Value 1.51
Price-to-Median-PS-Value ranked lower than
55.44% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
ILMN: 1.51
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.4, Med: 1.02, Max: 66.74
Current: 1.51
0.4
66.74
Price-to-Peter-Lynch-Fair-Value 2.99
Price-to-Peter-Lynch-Fair-Value ranked higher than
50.00% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
ILMN: 2.99
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 1.36, Med: 2.56, Max: 9.54
Current: 2.99
1.36
9.54
Price-to-Graham-Number 6.78
Price-to-Graham-Number ranked lower than
100.00% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 49.42, Med: 3.98, Min: 0.39
ILMN: 6.78
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 3.52, Med: 6.43, Max: 49.59
Current: 6.78
3.52
49.59
Earnings Yield (Joel Greenblatt) % 1.98
Earnings Yield (Greenblatt) ranked higher than
66.79% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
ILMN: 1.98
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 0.4, Med: 2.5, Max: 5.9
Current: 1.98
0.4
5.9
Forward Rate of Return (Yacktman) % 21.14
Forward Rate of Return ranked higher than
92.86% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
ILMN: 21.14
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -0.4, Med: 21.2, Max: 23.3
Current: 21.14
-0.4
23.3

More Statistics

Revenue (TTM) (Mil) $ 3,396
EPS (TTM) $ 5.72
Beta 1.27
Volatility % 32.33
52-Week Range $ 268.62 - 372.61
Shares Outstanding (Mil) 147

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N